17 / 32
Studies in mHSPC: what patient populations
were included?
ADT+AA+P vs ADT
ADT+Doc vs ADT
LATITUDE*
1
STAMPEDE
(Arm G)
2,3
GETUG-AFU 15
4
CHAARTED
5,6
STAMPEDE
(Arm C)
7
Total sample size, n
1199
1917
385
790
1776
Patients with mHSPC
100%
52%
100%
100%
61%
Patients with high-
risk/high volume mHSPC 100%
NE
47.5% (183)
65 % (513)
NE
Patients with
de novo
M1 100%
49%
71%
72.8%
58%
Patients with visceral
metastasis
17.3%
3%
14.5%
15.6%
3.8%
Patients with Gleason
Score ≥8
98%
74.9%
56.1%
61.3%
70.1%
Not head-to-head comparison studies
* All LATITUDE patients had high-risk and newly diagnosed metastatic disease
NE, not evaluated
1
Fizazi K et al. N Engl J Med 2017;377(4):352-360;
2
James N et al. J Clin Oncol 2017;35(15):LBA5003;
3
James N et al. N Engl J Med 2017;377(4):338-351;
4
Gravis G et al.
Eur Urol 2016;70(2):256-62;
5
Sweeney C et al. N Engl J Med 2015;378(8):737-746;
6
Sweeney C et al. Ann Oncol 2016;27(suppl 6):720PD;
7
James N et al. Lancet 2016;387(10024):1163-77
HIGH RISK (HR)
1
At least 2 of 3:
•
≥3 bone lesions
•
Visceral metastasis
•
Gleason score ≥8
HIGH VOLUME (HV)
4,5
At least 1 of 2:
•
≥4 bone lesions with
≥1 beyond the
vertebral bodies/pelvis
•
Visceral metastasis
Studies in mHSPC: what patient populations
were included?
ADT+AA+P vs ADT
ADT+Doc vs ADT
LATITUDE*
1
STAMPEDE
(Arm G)
2,3
GETUG-AFU 15
4
CHAARTED
5,6
STAMPED
(Arm C)
7
Total sample size, n
1199
1917
385
790
1776
Patients with mHSPC
100%
52%
100%
100%
61%
Patients with high-
risk/high volume mHSPC 100%
NE
47.5% (183)
65 % (513)
NE
Patients with
de novo
M1 100%
49%
71%
72.8%
58%
Patients with visceral
metastasis
17.3%
3%
14.5%
15.6%
3.8%
Patients with Gleason
Score ≥8
98%
74.9%
56.1%
61.3%
70.1%
Not head-to-head comparison st
* All LATITUDE patients had high-risk and newly diagnosed metastatic disease
NE, not evaluated
1
Fizazi K et al. N Engl J Med 2017;377(4):352-360;
2
James N et al. J Clin Oncol 2017;35(15):LBA5003;
3
James N et al. N Engl J Med 2017;377(4):338-351;
4
Gra
Eur Urol 2016;70(2):256-62;
5
Sweeney C et al. N Engl J Med 2015;378(8):737-746;
6
Sweeney C et al. Ann Oncol 2016;27(suppl
7
James N et al. Lancet 2016;387(1002
HIGH RISK (HR)
1
At least 2 of 3:
•
≥3 bone lesions
•
Visceral metastasis
•
Gleason score ≥8
HIGH VOLUME (HV)
4,5
At least 1 of 2:
•
≥4 bone lesions with
≥1 beyond the
vertebral bodies/pelvis
•
Visceral metastasis